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INTRODUCTION
Nasal polyposis is a chronic inflammatory disease of the up-
per airways often associated with asthma. Although the precise 
mechanisms underlying the genesis and development of nasal 
polyposis are not fully well defined, nasal polyps are character-
ized by markedly increased numbers of eosinophils, T-helper 
type 2 (Th2) type lymphocytes, fibroblasts, goblet cells and mast 
cells.
1-4 Recent studies have focused on identifying the mecha-
nisms of eosinophil chemotaxis, activation, and survival, in ad-
dition to their possible link to gross histopathologic changes 
such as pseudocyst formation. Interleukin (IL)-5, transforming 
growth factor-beta, RANTES and eotaxin seem to be crucial 
players in the regulation of eosinophilic inflammation and ex-
tracellular matrix breakdown. Studies have also demonstrated 
a strong local upregulation of IL-13, thymus and activation-reg-
ulated chemokine (TARC), immunoglobulin E (IgE) synthesis 
with the formation of specific IgE to Staphylococcus aureus en-
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terotoxins, suggesting a possible role of superantigens in these 
pathologic processes.
5-7
Thymic stromal lymphopoietin (TSLP) is an IL-7 like cytokine 
molecule that binds to TSLP receptor (TSLPR) consisting of the 
IL-7 receptor α-chain (IL-7Rα) and a common γ receptor-like 
chain (TSLP-γ).
8-10 As the name suggests, it was originally isolat-
ed from a mouse thymic stromal cell line and characterized as 
a lymphocyte growth factor.
11 TSLP is produced by several cell 
types, including human epithelial cells and stromal and mus-
cular cells.
12,13 It was first identified as a growth factor for B cells 
in a thymic stromal cell line. This cytokine presents a structural 
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Purpose:  Nasal polyposis is a chronic inflammatory disease of the upper airways often associated with asthma and characterized by markedly in-
creased numbers of eosinophils, Th2 type lymphocytes, fibroblasts, goblet cells and mast cells. Previous studies have shown elevated levels of thy-
mic stromal lymphopoietin (TSLP) in atopic diseases like asthma, atopic dermatitis and mainly in animal models of allergic rhinitis (AR). Here, we in-
vestigated the expression of TSLP in nasal polyps from atopics and non-atopics in comparison with the nasal mucosa and its potential role in nasal 
polyposis.  Methods:  Messenger RNA expression for TSLP, thymus and activation-regulated chemokine (TARC) and macrophage derived chemo-
kine (MDC) in nasal polyps and nasal mucosa of atopics and non-atopics was analyzed by real time PCR. Immunoreactivity for TSLP in nasal polyps 
and in the nasal mucosa of patients with AR and non-allergic rhinitis (NAR) was analyzed by immunohistochemistry. Eosinophil counts was analyzed 
by Wright-Giemsa staining and nasal polyp tissue IgE, by ELISA.  Results:  Messenger RNA expression for TSLP,TARC and MDC was markedly high-
er in nasal polyps as compared to the allergic nasal mucosa. Immunoreactivity for TSLP was detected in epithelial cells, endothelial cells, fibroblasts 
and inflammatory cells of the nasal mucosa and nasal polyps. The number of TSLP+ cells was significantly greater in the nasal mucosa of AR than 
NAR patients. The number of TSLP+ cells in nasal polyps from atopics was significantly greater than that of non-atopics and that in the allergic na-
sal mucosa. The number of TSLP+ cells correlated well with the number of eosinophils and the levels of IgE in nasal polyps.  Conclusions:  The 
high expression of TSLP in nasal polyps and its strong correlation to eosinophils and IgE suggest a potential role for TSLP in the pathogenesis of na-
sal polyps by regulating the Th2 type and eosinophilic inflammation.
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and functional homology to IL-7.
9 TSLPR is a heterodimer con-
sisting of a specific TSLPR and IL-7Rα. By interacting with the 
heterodimeric receptor IL-7Rα/TSLPR, TSLP appears to initiate 
signal transduction through signal transducer and activator of 
transcription (STAT) 3 and STAT5 activation.
10,14-16
It is established that Th2 cytokines IL-4, IL-5, and IL-13 play 
essential roles in the development of allergic disease.
7,17,18 TSLP 
stimulates human myeloid dendritic cells (DCs) which unique-
ly express the heterodimeric TSLP receptor to promote Th2 po-
larization of inflammatory CD4+ T cells that primes CD4+ T cells 
to undergoing Th2 differentiation.
15 In fact, TSLP instructs den-
dritic cells to induce a Th2 response. These TSLP-DC stimulate 
CD4(+)T cells to induce a proallergic cytokine profile, indicat-
ing an important role for TSLP plays in allergic diseases.
15
Recently, the expression and role of TSLP in atopic diseases 
like asthma and atopic dermatitis were investigated and the el-
evated levels of TSLP in these atopic diseases and the specific 
expression in epithelial cells suggest its ability to trigger den-
dritic cell-mediated activation of Th2 inflammatory respons-
es.
19 Although few studies have shown TSLP expression in the 
nasal mucosa
20 especially nasal epithelial cells and in the ani-
mal allergic rhinitis (AR) model,
21 there are no studies describ-
ing the expression or role of TSLP in nasal polyps. Furthermore, 
although eosinophilic nasal polyps is characterized by Th2 in-
flammation, the mechanism underlying the predominance of 
Th2 responses still needs to be clarified. Recently, we reported 
that nasal polyp fibroblasts in vitro can produce TSLP in re-
sponse to stimulation by tumor necrosis factor (TNF) alpha and 
that combined stimulation with TNF-alpha + a Th2 cytokine 
(IL-4 orIL-13) enhanced the production of TSLP from nasal 
polyp fibroblasts.
5,6 In the present study, we investigated the ex-
pression of TSLP in nasal polyps from atopic as well as non-atop-
ics in comparison with that in the nasal mucosa of patients with 
allergic and non-allergic rhinitis, by immunohistochemistry 
and its relation to eosinophil inflammation and IgE.
The airway is often exposed to not only Th2 cytokines but also 
bacterial products such as lipopolysaccharides (LPS). A CC che-
mokine, TARC, is a potent chemoattractant for Th2 cells. We re-
cently demonstrated increased IL-4 and LPS induced TARC 
production by nasal polyp fibroblasts
5,22 that may play an im-
portant role in the recruitment of Th2 cells into the sinus muco-
sa as well as nasal polyps. We therefore also examined the 
mRNA expression of TSLP, TARC, and macrophage derived 
chemokine (MDC) in nasal polyps from atopics versus non-
atopics and nasal mucosa from patients with AR.
MATERIALS AND METHODS
Patient profile
Twenty patients with nasal polyposis were included in this 
study. Of the twenty patients with nasal polyposis one patient 
had aspirin induced asthma. Ten of the twenty patients with na-
sal polyposis were atopic (M:F=8:2; mean age, 42.9±14.5 years) 
and 10 were non-atopic (M:F=10:0; mean age, 45.8±18.3 years). 
All the ten atopic patients with nasal polyposis had typical clini-
cal symptoms of nasal allergy comprising sneezing, rhinorrhea 
and nasal congestion and positive serum specific IgE as ana-
lyzed by radioallergosorbent test (RAST). Of the 10 atopic pa-
tients with nasal polyposis and nasal allergy, 6 had perennial al-
lergic rhinitis (PAR) to house dust (HD) mite (RAST ranged from 
0.84-64.25 IU/mL), 4 had seasonal allergic rhinitis (SAR) to Jap-
anese cedar pollen (RAST ranged from 0.48-59.12 IU/mL) and 
1 had serum specific IgE to both HD mite and Japanese cedar 
pollen and 1 had positive serum specific IgE to dog (RAST 
0.43IU/mL). In this study, we also included ten patients with 
AR (M:F=8:2; mean age, 40.4±13.5 years), and 10 with non-al-
lergic rhinitis (NAR) (M:F=9:1; mean age, 35±12.25 years).
The diagnosis of AR was done on the basis of a typical history 
of clinical symptoms of sneezing, rhinorrhea and nasal conges-
tion, clinical examination by anterior rhinoscopy and positive 
serum specific IgE by RAST. All the 10 patients with AR had PAR 
to HD mite (RAST ranged from 0.52 to 58.50 IU/mL), seven of 
them also had SAR to Japanese cedar pollen (RAST ranged from 
0.57 to 38.10 IU/mL). Patients with NAR had hypertrophied tur-
binates but with no symptoms of nasal allergy. All patients were 
symptomatic at the time of collecting the specimens and none 
of them had received immunotherapy in the past. Nasal polyp 
specimens and nasal mucosal tissue samples were collected at 
surgery performed as part of the treatment either for the remov-
al of nasal polyps or for the resection of hypertrophied turbi-
nates. All medications were prohibited for at least one month 
prior to surgery. The study was approved by the Nippon Medi-
cal School Medical Ethics Committee and informed consent 
was taken from all patients.
Collection and processing of specimens
Nasal polyp tissues were obtained at surgery done as a part of 
the treatment for the removal of nasal polyps (polypectomy/
functional endoscopic sinus surgery). Nasal mucosal specimens 
were obtained at surgery (conchotomy) done for the treatment 
of hypertrophied turbinates. Both nasal polyp specimens and 
nasal mucosal tissue specimens (3×4 mm) were rinsed in Phos-
phate buffered saline (PBS) pH 7.6, and then processed for im-
munohistochemistry, PCR or ELISA as described below.
Real-time PCR analysis for mRNA expression of TSLP, TARC 
and MDC
By real time PCR we analyzed the mRNA expression of TSLP, 
TARC and MDC in nasal polyps from atopics, non-atopics and 
in the allergic nasal mucosa. Total cellular RNA was extracted 
from nasal mucosa and nasal polyps and purified using an 
RNeasy mini kit (Qiagen GmbH, Strasse, Germany). cDNAs 
were prepared from 1 µg of total RNA by reverse transcription 
at 37°C for 60 minutes and at 95°C for 5 minutes using the High Kimura et al.
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capacity RNA-to-cDNA kit (Applied Biosystems, Foster City, CA, 
USA) according to the manufacturers’ protocols. Quantitative 
real-time PCR was carried out using the TaqMan assay and Ap-
plied Biosystems 7500 Fast Real Time PCR System (Applied 
Biosystems). The quantitative real-time PCR assay was based 
on primers that specifically amplify TSLP, TARC and MDC. The 
primers and fluorogenic probes for TSLP (Hs00263639_m1), 
MDC (Hs01574247_m1) and TARC (Hs00171074_m1) and 
β-actin (Hs99999903_m1) were purchased from Applied Bio-
systems. The amplification efficiency of the specific primers 
and β-actin were validated in a preliminary experiment. For the 
PCR analysis, each sample was run in triplicates in separate 
tubes to permit quantification of TSLP, TARC and MDC genes 
normalized to β-actin. The PCR condition consisted of initial 
denaturation step of 95°C for 20 seconds, followed by 50 cycles 
of amplification at 95°C for 3 seconds and at 60°C for 30 seconds.
Data analysis
Data analysis was performed using 7500 software version 2.0.4 
(Applied Biosystems). For quantitative analysis, we used the ΔΔ 
Ct method according to the manufacturer’s instructions (Ap-
plied Biosystems: Relative quantitation of gene expression ABI 
Prism 7700 sequence detection system. User Bulletin 2;1997).
23 
The threshold cycles were used to calculate arbitrary mRNA 
concentrations by the difference of Ct values between samples 
and calibrator (qPCR Human Reference Total RNA, Clontech 
Laboratories). The level of TSLP, MDC and TARC mRNA was 
normalized to the level of β-actin mRNA.
Immunohistochemistry for the detection of TSLP
Nasal polyp and nasal mucosa tissue specimens were first fixed 
in periodate lysine paraformaldehyde (PLP) and then incubat-
ed for 4 hours each in varying gradients of sucrose from 10 to 
20% in PBS. Subsequently, the specimens were embedded in 
OCT compound, frozen in liquid nitrogen and stored at -80°C 
till further use. To investigate the expression of TSLP and to de-
tect the localization of TSLP in nasal polyps and the nasal mu-
cosa, immunohistochemistry was performed. For immunohis-
tochemistry, frozen sections of PLP fixed specimens at 5 µm 
thickness were cut using a cryostat (Sakura Finetek, Tokyo, Ja-
pan), air-dried for 30 minutes and then fixed in acetone for 10 
minutes. Immunohistochemistry was performed using the per-
oxidase-based Avidin-Biotin Complex (ABC) method (Vecta-
stain ABC kits, Burlingame, CA, USA). Briefly, the acetone fixed 
sections were rehydrated by incubation in Tris-buffered saline 
(TBS) pH 7.4. Thereafter, the specimens were incubated in 10% 
H2O2 for 30 minutes to block endogeneous peroxidase. After 2 
rinses in TBS, the specimens were incubated in Protein Block 
Serum (Dako Japan, Tokyo, Japan). After 2 rinses in TBS, the 
sections were then incubated for 48 hours at 4°C with the prima-
ry antibody, the mouse anti-human TSLP (R&D system, Min-
neapolis, MN, USA) at (10 µg/mL) optimal concentration. Sec-
tions were then rinsed twice in TBS and Biotin blocking was 
done. Subsequently, the sections were incubated in the horse 
anti-mouse immunoglobulin (Dako Japan) for 30 minutes at 
room temperature. After 2 rinses in TBS, the sections were in-
cubated in the ABC regent (Dako Japan) for 30 minutes at room 
temperature followed by incubation in the AEC substrate. The 
sections were then rinsed twice in distilled water (DW), incu-
bated for 30 seconds in Mayer’s hematoxylin and rinsed again 
twice in DW. Finally, the specimens were mounted in Dako gel. 
For negative control, the primary antibodies were substituted 
with an irrelevant isotype matched mouse IgG (IgG2a) (Dako 
Japan).
Cell counting
The number of positively stained TSLP+ cells was counted un-
der an Olympus microscope in 6 randomly selected visual 
fields using an objective micrometer in an area of 0.202 mm
2 
and at a magnification of 400 HPF. The average of 6 fields was 
taken as the cell count for that section.
Analysis of TSLP immunoreactivity in epithelial cells
TSLP expression in nasal epithelial cells was scored using an 
Image J analysis system (National Institute of Mental Health, 
Bethesda, MD, USA).The density of staining was converted into 
a numerical value by using image J, a public domain Java image 
processing program.
24 The expression in the epithelial cells was 
measured relative to the expression in the lamina propria.
Analysis for the detection of eosinophils and cell counting
Wright-Giemsa staining was used to identify the eosinophils 
in the nasal polyp and nasal mucosa tissue sections. The num-
ber of eosinophils was counted in 6 randomly selected visual 
fields using an objective micrometer in an area of 0.202 mm
2 
and at a magnification of 400 HPF. The average of the 6 fields 
was taken as the final count for the section.
ELISA analysis for the detection of IgE in nasal polyps
Nasal polyp tissues were homogenized using ultrasonification 
and high speed centrifugation and the supernatants were col-
lected and stored at -20°C. The levels of IgE in the nasal polyp 
extracts were measured using the IgE specific ELISA kits (BET, 
Montogomery, TX, USA). The minimum detectable level of IgE 
was 15.6 ng/mL.
Statistical analysis
The data presented are expressed as mean±SEM. Statistical 
significance for intergroup comparisons was determined by the 
Mann-Whitney U test. Differences were considered significant 
only when the P values was less than 0.05. Correlation between 
the number of TSLP+ cells and eosinophils in the nasal polyps 
and nasal mucosa as well as between the number of TSLP+ cells 
and IgE levels in nasal polyps was determined using the Spear-TSLP in Nasal Polyps
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man’s coefficient. All statistical analysis was performed using 
the SPSS 11.0 version (SPSS, Inc., Chicago, IL, USA).
RESULTS
Messenger RNA expression of TSLP, TARC and MDC in nasal 
polyps and nasal mucosa
We analyzed the mRNA expression of TSLP, TARC and MDC 
in the nasal polyps from atopics, non-atopics and allergic nasal 
mucosa by real time PCR. Messenger RNA expression of TSLP, 
TARC and MDC were detected in nasal polyps from atopics, 
non-atopic nasal polyps and in the allergic nasal mucosa. The 
mRNA expression of TSLP as well as TARC and MDC was mark-
edly higher in nasal polyps from atopics as compared to the al-
lergic nasal mucosa (Fig. 1) and relatively higher than in nasal 
polyps from non-atopics.
Immunohistochemical localization of TSLP in the nasal mucosa 
and nasal polyps
We analyzed the expression of TSLP in the nasal mucosa of 
patients with AR and NAR. TSLP expression was detected in the 
epithelial cells, endothelial cells and in inflammatory cells in 
the nasal mucosa of patients with NAR (Fig. 2A) and AR (Fig. 
2C). Negative control did not show any immunoreactivity for 
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Fig. 1.  Relative messenger RNA expression of thymic stromal lymphopoietin 
(TSLP), thymus and activation-regulated chemokine (TARC) and macrophage de-
rived chemokine (MDC) in nasal polyps (atopic and non-atopic) and allergic na-
sal mucosa. The mRNA expression was analyzed by real time PCR as described 
in the text. The quantitative real-time PCR assay was based on primers that 
specifically amplify TSLP, TARC and MDC. The mRNA expression of TSLP as 
well as TARC and MDC was markedly higher in nasal polyps from atopics as 
compared to the allergic nasal mucosa and relatively higher than in nasal pol-
yps from non-atopics.
A+ Po, nasal polyps from atopics (n=4); A- Po, nasal polyps from non-atopics 
(n=3); A+ NM, nasal mucosa from allergic rhinitis patients (n=3).
Fig. 2.  Immunoreactivity and localization of thymic stromal lymphopoietin 
(TSLP) in the nasal mucosa. The immunoreactivity for TSLP was analyzed by im-
munohistochemistry using the peroxidase-based Avidin-Biotin Complex (ABC) 
method as described in the text. TSLP immunoreactivity is shown as in (A) in 
the nasal mucosa of patients with non-allergic rhinitis (NAR). TSLP was ex-
pressed strongly especially in epithelial cells. (B) Negative control in NAR 
shows no immunoreactivity for TSLP. (C) In allergic rhinitis nasal mucosa. TSLP 
was strongly expressed in epithelial cells, and inflammatory cells. (D) Negative 
control shows no immunoreactivity for TSLP (magnification ×400 HPF).
A
C
B
D
Fig. 3.  Immunoreactivity and localization of thymic stromal lymphopoietin 
(TSLP) in nasal polyps. The immunoreactivity for TSLP was analyzed by immu-
nohistochemistry using the using the peroxidase-based Avidin-Biotin Complex 
(ABC) method as described in the text. TSLP immunoreactivity is as shown in 
(A). In nasal polyps from non-atopics, TSLP was expressed strongly especially 
in epithelial cells. (B) Negative control shows no immunoreactivity for TSLP. (C) 
In nasal polyps from atopics. TSLP expression was detected in the epithelial 
cells, endothelial cells, fibroblasts and in inflammatory cells in nasal polyps 
from both atopics and non-atopics. Stronger immunoreactivity for TSLP was de-
tected in the nasal polyps from atopics. (D) Negative control shows no immuno-
reactivity for TSLP (magnification ×400 HPF).
A B
C DKimura et al.
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TSLP (Fig. 2B and D). We also analyzed the expression of TSLP 
in the nasal polyps of atopic patients as well as nasal polyps from 
non-atopic patients. TSLP expression was detected in the epi-
thelial cells, endothelial cells, fibroblasts and in inflammatory 
cells in nasal polyps from both non-atopics (Fig. 3A) and atop-
ics (Fig. 3C). Negative control did not show any immunoreac-
tivity for TSLP (Fig. 3B and D).
Numbers of TSLP+ cells in the nasal mucosa and nasal polyps
The number of TSLP positive cells in the nasal mucosa of pa-
tients with AR was significantly greater than that in the nasal 
mucosa of patients with NAR (AR, 33.9±7.4/HPF; NAR, 17.5±
5.2/HPF, P<0.05) (Fig. 4A). The number of TSLP positive cells 
in nasal polyp from atopics was significantly greater than that of 
non-atopics (A+Po, 66.2±10.2/HPF; A-Po, 26.7±10.8/HPF; 
P<0.05) (Fig. 4B). Moreover, the number of TSLP+ cells in nasal 
polyps from atopics was also greater than that in the nasal mu-
cosa of AR patients (Fig. 4C). No significant difference was found 
in the number of TSLP+ cells between non-atopic nasal polyps 
and nasal mucosa of NAR (Fig. 4D).
Expression of TSLP in epithelial cells of nasal polyps and nasal 
mucosa
The expression of TSLP in nasal epithelial cells of patients with 
AR was significantly greater than that in the nasal mucosa of 
patients with NAR (AR, 1.53±0.14; NAR, 1.29±0.10; P<0.05) 
(Fig. 5A). Although the TSLP expression in the nasal polyp epi-
thelial cells of atopic patients was slightly higher than of non-
atopics, no significant difference was detected (atopic polyp, 
1.58±0.27; non-atopic polyp, 1.41±0.23) (Fig. 5B). No differ-
ence was detected in the expression of TSLP in epithelial cells 
of nasal polyps from atopics and nasal mucosa of AR patients 
(Fig. 5C) or between nasal polyp epithelial cells of non-atopics 
and nasal epithelial cells of NAR patients (Fig. 5D).
Eosinophils in nasal polyps
The number of eosinophils in nasal polyps was significantly 
greater in the nasal polyps as compared to the nasal mucosa of 
AR patients (nasal polyp, 22.5±27.0/HPF; nasal mucosa of AR 
patients, 4.33±4.82/HPF; P<0.001) Furthermore, the number 
of eosinophils in nasal polyps of atopics was significantly great-
er than that in nasal polyps from non-atopics (atopic polyp, 
40.6±30.6/HPF; non-atopic polyp, 6.7±6.0/HPF; P<0.001).
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Fig. 4.  The number of thymic stromal lymphopoietin (TSLP) positive cells in the 
nasal mucosa and nasal polyps. Immunohistochemistry for TSLP was per-
formed as described in the text. Positively stained cells were counted as de-
scribed in the text in an area on 0.202 mm
2×400 HPF. (A) The number of TSLP 
positive cells in the nasal mucosa of patients with allergic rhinitis (AR) was sig-
nificantly greater than that in the nasal mucosa of patients with non-allergic 
rhinitis (NAR) (*P<0.01). (B) The number of TSLP positive cells in nasal polyps 
from atopics was significantly greater than that of non-atopics (*P<0.01). (C) 
The number of TSLP positive cells was greater in the nasal polyps of atopics as 
compared to that of AR nasal mucosa (*P<0.01). (D) No significant difference 
was found in the number of TSLP+ cells between non-atopic nasal polyps and 
nasal mucosa of NAR patients.
A+ Po, nasal polyps from atopics; A- Po, nasal polyps from non-atopics; A+ NM, 
nasal mucosa from AR patients; A- NM, nasal mucosa from NAR patients.
Fig. 5.  Epithelial cell expression of thymic stromal lymphopoietin (TSLP) in the 
nasal mucosa and nasal polyps. TSLP expression in nasal epithelial cells was 
scored using an Image J analysis system as described in the text. (A) The ex-
pression of TSLP in nasal epithelial cells of patients with allergic rhinitis (AR) 
was significantly greater than that in the nasal mucosa of patients with non-al-
lergic rhinitis (NAR) (*P<0.05). (B) TSLP expression in the nasal polyp epithelial 
cells of atopic patients was slightly higher than that of non-atopics but no sig-
nificant difference was detected. (C) No difference was detected in the expres-
sion of TSLP in epithelial cells of nasal polyps from atopics and nasal mucosa 
of AR patients. (D) No difference was detected between nasal polyp epithelial 
cells of non-atopics and nasal epithelial cells of NAR patients.
A+ Po, nasal polyps from atopics; A- Po, nasal polyps from non-atopics; A+ NM, 
nasal mucosa from AR patients; A- NM, nasal mucosa from NAR patients.TSLP in Nasal Polyps
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Level of IgE in nasal polyps by ELISA
The level of IgE in nasal polyps was measured by IgE specific 
ELISA kits as described in the methods section. The mean level 
of IgE in nasal polyps was 97.6±75.0 ng/mL.
Correlation between the number of TSLP positive cells and 
eosinophils in nasal polyps
To understand the relation between TSLP and eosinophilic 
inflammation in nasal polyps, we analyzed the correlation be-
tween TSLP+ cells and number of eosinophils in nasal polyps. 
There was a statistically significant correlation between the 
numbers of TSLP+ cells and the number of eosinophils in nasal 
polyps (r=0.78; P<0.001) (Fig. 6).
Correlation between the number of TSLP positive cells and IgE 
in nasal polyp
There was a statistically significant correlation between the 
number of TSLP+ cells in nasal polyps and the level of IgE in 
nasal polyps (r=0.75; P<0.05).
DISCUSSION
TSLP plays an important role in the DC-mediated activation 
of Th2 inflammatory responses.
12,18 In this study, we detected 
the in vivo expression of TSLP mRNA and protein in nasal pol-
yps of patients with nasal polyposis. We also detected that the 
expression of TSLP in nasal polyps was significantly greater than 
that in the allergic nasal mucosa irrespective of whether the na-
sal polyp patients were atopic or non-atopic. Furthermore, the 
expression of TSLP was greater in nasal polyps from atopics as 
compared to those from non-atopics. To the best of our knowl-
edge this is the first report of TSLP expression in nasal polyps.
As reported in atopic dermatitis and asthma, TSLP was mainly 
localized to the epithelial cells.
17,25 Epithelial cell-derived TSLP 
can play a major role not only in AR but also in nasal polyps as 
a master by inducing a dendritic cell-mediated Th2-type aller-
gic inflammation. However, Corrigan et al reported TSLP ex-
pression in inflammatory cells in atopic dermatitis.
26 In the pres-
ent study, immunoreactivity for TSLP was also detected in en-
dothelial cells, fibroblasts and inflammatory cells in nasal pol-
yps.
Although we did not perform double staining in this study, 
morphologically some of the TSLP+ inflammatory cells ap-
peared to be mast cells. This supposed expression of TSLP in 
mast cells, coupled with the reports of TSLP+ mast cells in ver-
nal conjunctivitis and allergic conjunctivitis, and consistent 
with previous studies that mast cells activated through the IgE 
receptor can express TSLP mRNA support the proposal
27 that 
mast cells are essential for TSLP expression in the epithelium. 
In another study TSLP expression was up-regulated predomi-
nantly in the nasal epithelium in the ovalbum in (OVA)-sensi-
tized and -nasally challenged mouse model of AR, which was 
abolished in mast cell-deficient WBB6F1-W/W(v) in compari-
son with control WBB6F1-+/+ mice and reduced in Fc receptor 
gamma chain (FcgammaR)-deficient mice, suggesting that 
mast cell regulation of epithelial TSLP expression, possibly via 
FcepsilonRI, plays an important role in the development of al-
lergic inflammation.
28 In this context, previously we and others 
have shown that mast cells are an important source of IL-4, IL-
13 and TNF-alpha and that IL-4, IL-13 in concert with TNF-al-
pha were capable of upregulating TSLP production from nasal 
polyp fibroblasts.
6 We also showed that nasal polyp fibroblasts 
in vivo expressed TSLP.
6 Taken together these results show that 
mast cells in nasal polyps may play an important role in regu-
lating TSLP expression in nasal polyp epithelial cells and fibro-
blasts. Furthermore, the increased mRNA expression of TSLP 
in nasal polyps was associated with increased mRNA expression 
of Th2 type chemokines namely TARC and MDC.
Recently, it was reported that TSLP produced by epithelial cells 
and keratinocytes can modulate mature CD4+ T-cell prolifera-
tion and survival through its interaction with dendritic cells.
29 
TSLP stimulates Th2 cytokine production, such as IL-13. Our 
results demonstrate high expression of TSLP in nasal epithelial 
cells of AR patients and a stronger expression in nasal polyp ep-
ithelial cells. Therefore, TSLP from nasal polyp epithelial cells 
can activate mast cells to produce Th2 type cytokines like IL-4 
Fig. 6.  Correlation between thymic stromal lymphopoietin (TSLP) and eosino-
phils in nasal polyps. There was a statistically significant correlation between 
the number of TSLP+ cells (A) and the number of eosinophils in nasal polyps (B) 
(r =0.78, P<0.05).
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and IL-13 that can contribute to eosinophilic inflammation by 
upregulation of eosinophil chemoattractants and adhesion 
molecules.
23 We previously showed that epithelial cells express 
HLA-DR and CD86 and Fcepsilon receptor alpha chain and 
that IL-4 can upregulate Fcepsilon alpha chain expression in 
nasal epithelial cells indicating an augmented antigen present-
ing activity.
30 Furthermore, the increased mRNA expression of 
TSLP in nasal polyps was associated with increased mRNA ex-
pression of other Th2 type chemokines namely TARC and 
MDC.
5,24
Emerging data have shown that the expression of TSLP was 
elevated in asthmatic airway. Besides, studies have revealed in 
animal model, the up-regulation of TSLP in nasal mucosa. Our 
study demonstrates that the excessive expression of TSLP in ep-
ithelial cells of patients with AR and nasal polyposis. TSLP pro-
duced by the epithelial interface, and may represent a mecha-
nism whereby environmental stimuli initiate Th2 responses to 
allergen, and through chemokine production retaining or at-
tracting in asthmatic airways.
20
Eosinophilic nasal polyps is characterized by a polarized Th2 
reaction and eosinophilic inflammation.
1,2,31 To further investi-
gate whether TSLP is associated in regulating eosinophil infil-
tration in nasal polyps, Wright Giemsa staining was performed 
to evaluate the numbers of eosinophils in the nasal polyps and 
the correlation between the number of TSLP+ cells and eosino-
phil numbers was analyzed. Our study showed a strong corre-
lation between the numbers of eosinophils in nasal polyps and 
numbers of TSLP+ cells. This result support the hypothesis that 
epithelial cells sourced TSLP may have a potential role in regu-
lating eosinophilic inflammation in the nasal polyps possibly 
via driving Th2 type inflammation that can upregulate eosino-
philic chemoattractants. While the relationship between TSLP 
and tissue eosinophilia deserves further study, the roles of TSLP 
in the survival and recruitment of mast cells in airway inflam-
mation is also interesting and need further studies.
In nasal polyps, high IgE concentrations have been reported 
indicating that IgE is produced locally.
32,33 Van Zele et al.
32 also 
reported a polyclonal hyper-immunoglobulinemia E, associat-
ed with the presence of IgE specific to Staphylococcus aureus 
enterotoxins, colonization with Staphylococcus aureus and in-
creased eosinophilic inflammation in a relevant subgroup of 
nasal polyp patients (about 50%). They also reported a strong 
correlation between IgE in nasal polyps and nasal eosinophils. 
Our results demonstrated high levels of IgE in nasal polyps and 
a good correlation between the levels of nasal polyp IgE and the 
number of TSLP+ cells in nasal polyps as well as between TSLP 
and eosinophils.
Mast cells release mediators upon stimulation that contribute 
to the pathogenesis of chronic airway disease, including the re-
cruitment and activation of Th2 lymphocytes. We previously 
demonstrated that mast cells can release IL-4 and IL-13 express 
the CD40 ligand and induce IgE synthesis locally in the nasal 
mucosa and that this was more IL-13 dependant.
34 
Allakhverdi et al.
25 showed partial suppression of IL-13 ex-
pression using anti-TSLP antibody in a mast cell-lesional, AD-
skin coculture model suggesting the role of TSLP in enhancing 
IL-13 production.
Sheahan et al.
35 demonstrated local IgE production in non-
atopic nasal polyposis also.
In summary, we found the increased in vivo expression of 
TSLP in the epithelial cells and infiltrating cells of patients with 
nasal polyps irrespective of their atopic status. The presence of 
Th2 type inflammation in nasal polyps from both atopic and 
non-atopic patients as well as a more severe form of Th2 type 
inflammation in nasal polyps as compared to the allergic nasal 
mucosa could in part be due to the differential and upregulated 
expression of TSLP in nasal polyps. These findings indicate a 
potential and crucial role for TSLP in role in the pathogenesis of 
severe chronic inflammation in nasal polyps via regulating the 
Th2 and eosinophilic inflammation.
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